Celon Pharma S.A.

Warsaw Stock Exchange CLN.WA

Celon Pharma S.A. Free Cash Flow Yield on January 14, 2025: -3.18%

Celon Pharma S.A. Free Cash Flow Yield is -3.18% on January 14, 2025, a 39.15% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Celon Pharma S.A. 52-week high Free Cash Flow Yield is -2.38% on October 18, 2024, which is 25.20% above the current Free Cash Flow Yield.
Celon Pharma S.A. 52-week low Free Cash Flow Yield is -5.61% on April 16, 2024, which is -76.44% below the current Free Cash Flow Yield.
Celon Pharma S.A. average Free Cash Flow Yield for the last 52 weeks is -4.03%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Warsaw Stock Exchange: CLN.WA

Celon Pharma S.A.

CEO	Dr. Maciej Wieczorek Ph.D.
IPO Date	Feb. 17, 2017
Location	Poland
Headquarters	ul. Ogrodowa
Employees	566
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.

Key trends

Past 5 years